Novartis AG (NVS)

87.07
0.72 0.83
NYSE : Health Technology
Prev Close 86.35
Open 87.64
Day Low/High 86.77 / 87.80
52 Wk Low/High 74.97 / 96.31
Volume 1.91M
Avg Volume 1.87M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 218.61B
EPS 5.50
P/E Ratio 16.08
Div & Yield 1.84 (2.14%)
European Week Ahead: GDP Data, Consumer Poll to Measure Brexit Damage

European Week Ahead: GDP Data, Consumer Poll to Measure Brexit Damage

Forward-looking purchasing managers' indices and earnings from beleaguered lender Deutsche Bank feature among the other release highlights.

Novartis May Be Too Generic

Novartis May Be Too Generic

Novartis stock has fallen 14% in the last year. A wave of generic drugs has wrecked results.

Roche Avastin Shortfall Pushes Quarterly Sales Below Forecasts

Roche Avastin Shortfall Pushes Quarterly Sales Below Forecasts

Shares in the stock decline only marginally as the pharmaceuticals group sticks with its full-year forecast.

Weak Start to Earnings Season, Crude Slump Pull Wall Street Into Selloff

Weak Start to Earnings Season, Crude Slump Pull Wall Street Into Selloff

Wall Street sells off as a disappointing quarterly performance from Alcoa heralds a poor start to the third-quarter earnings season and crude oil retreats from highs.

Stocks at Three-Week Lows as Alcoa Heralds Poor Start to Earnings Season

Stocks at Three-Week Lows as Alcoa Heralds Poor Start to Earnings Season

Stock losses accelerate on Tuesday afternoon as a disappointing quarterly performance from Alcoa heralds a poor start to the third-quarter earnings season.

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.

Analyst Says Cooper is Poised to Gain Market Share

Analyst Says Cooper is Poised to Gain Market Share

A KeyBanc Capital Markets analyst increases his price target on the stock to $221 from $199.

Analysts' Actions -- Qualcomm, Walmart, Autozone and More

Analysts' Actions -- Qualcomm, Walmart, Autozone and More

Here are Friday's top research calls, including upgrades for Casey's and Qualcomm and downgrades for AutoZone and Mylan.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CPHD, KODK, PINC, SRLP Downgrades: APU, ATU, AZO, BDL, GATX, GRA, HLT, MYL, NVS, TI.A, VG Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

5 Big Breakout Trades You Should Have in Your Portfolio This Fall

5 Big Breakout Trades You Should Have in Your Portfolio This Fall

Here's a technical look at how to trade some of the biggest stocks on Wall Street.

Kite Pharma Claims CAR-T Trial Victory, FDA Filing Next

Kite Pharma Claims CAR-T Trial Victory, FDA Filing Next

Kite Pharma's CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with an aggressive form of lymphoma, the company said Tuesday.

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.

Why There Is Upside for Incyte Despite Recent Selloff

Why There Is Upside for Incyte Despite Recent Selloff

The company's share price despite reporting better-than-expected earnings and revenue and

Stocks Retreat From Records as Health Care Slumps

Stocks Retreat From Records as Health Care Slumps

Stocks retreat from record highs on Monday as a selloff in health care overshadows a rally in energy.

Stocks Fall as Health Care Selloff Counters Energy Rally

Stocks Fall as Health Care Selloff Counters Energy Rally

Stocks pull slightly lower on Monday as a selloff in health care squares off against a rally in energy.

How Will Novartis (NVS) Stock React to Asthma Pill Trial Success?

How Will Novartis (NVS) Stock React to Asthma Pill Trial Success?

Novartis (NVS) is developing a new asthma pill that demonstrated promising results in a small clinical trial.

Health Care Drags Stocks Away From Records

Health Care Drags Stocks Away From Records

Stocks pull lower on Monday morning as a selloff in health care sours the jobs-inspired rally that pushed benchmark indices to record highs last week.

3 Stocks Pushing The Drugs Industry Downward

3 Stocks Pushing The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Roche Beats First-Half Forecasts as Cancer Drug Sales Rise

Roche Beats First-Half Forecasts as Cancer Drug Sales Rise

The Swiss pharmaceuticals company confirms a forecast for full-year sales to increase in the low to mid-single digits, and for earnings per share to grow faster than revenue.

Novartis Shares Slip Tuesday on Falling Profit

Novartis Shares Slip Tuesday on Falling Profit

Shares of the global healthcare company, Novartis, are down after it saw its profits fall in the second quarter.

Novartis (NVS) Stock Down on Profit Warning

Novartis (NVS) Stock Down on Profit Warning

Novartis (NVS) stock is lower in pre-market trading on Tuesday after cautioning that full-year profit could slide on more investments in its heart-failure drug.

European Markets Extend Losses as Brexit Shreds Confidence Index

European Markets Extend Losses as Brexit Shreds Confidence Index

A closely watched market sentiment indicator points to gloom in Germany and the euro area, while U.K. price growth picks up pace.

Novartis Second-Quarter Earnings, Revenue Fall Less Than Forecast

Novartis Second-Quarter Earnings, Revenue Fall Less Than Forecast

The pharmaceuticals company, led by CEO Joe Jiminez, had its first full quarter of generic competition for its Gleevec cancer drug.

3 Stocks Dragging In The Drugs Industry

3 Stocks Dragging In The Drugs Industry

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta

Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta

At least one company follower believes the divestiture of Shire's Neurology division for as much as $13 billion would be a logical next move.

X(encor) Marks the Spot For Potential Gains

X(encor) Marks the Spot For Potential Gains

You have to be impressed by the breadth of XNCR's pipeline and significant partnerships with major players.

Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks

Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks

Juno Therapeutics reminds investors yet again that the business of biotech -- developing new medicines that are effective and reasonably safe -- is hard to get right.

These 5 Big Stocks Are Breaking Out This Summer

These 5 Big Stocks Are Breaking Out This Summer

Here's a technical look at how to trade some of the biggest stocks on the market right now.

'Mad Money' Lightning Round: You Should Be Buying Visa

'Mad Money' Lightning Round: You Should Be Buying Visa

Cramer says Wynn is fantastic but he's avoiding Valeant.

Jim Cramer's 'Mad Money' Recap: Thank the Short-Sellers for This Continued Rally

Jim Cramer's 'Mad Money' Recap: Thank the Short-Sellers for This Continued Rally

When short-sellers get caught leaning the wrong way, that's a recipe for explosive moves to the upside, Cramer says.

TheStreet Quant Rating: A- (Buy)